Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7625 - 7632 of 12085 results

Federal Circuit Corrects the Board’s “Too Exacting” Diligence Standard
November 21, 2016| Blog| Viewpoint

Five Important Themes to Watch in the Reform of FDA’s Off-Label Communications Policy
November 21, 2016| Blog| Viewpoint

Massachusetts Long Term Care Facility Regulations – Proposed Amendments
November 21, 2016| Blog| Viewpoint

Promise to Repeal the ACA Poses Threat to MACRA Implementation
November 21, 2016| Blog| Viewpoint

Emboldened, the FTC Seems Ready to Fight More Mergers
November 21, 2016| News

Trump and Employment-Based Immigration: What’s Next?
November 21, 2016| News

Long-Awaited High Skilled Worker Regulations Published by the Department of Homeland Security
November 21, 2016| Alert| Viewpoint

Intellectual Ventures Petitions Federal Circuit for Full Court Review
November 18, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
